Search research articles
Contact Us
Filters
Showing results (81-90 of 113) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
The Oncologist
|
July 4, 2025
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
Andrew J Wagner, William D Tap, Sebastian Bauer, et al.
NPJ Precision Oncology
|
January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Sandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer
Mary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Cancer
|
June 8, 2019
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
Shreyaskumar Patel, Margaret von Mehren, Damon R Reed, et al.
Cancer Communications (London, England)
|
May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2013
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates
Janelle M Meyer, Kelly S Perlewitz, James B Hayden, et al.
Journal of Gynecologic Oncology
|
April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Young Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
JAMA Oncology
|
February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033
Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 113) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
The Oncologist
|
July 4, 2025
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
Andrew J Wagner, William D Tap, Sebastian Bauer, et al.
NPJ Precision Oncology
|
January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Sandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer
Mary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Cancer
|
June 8, 2019
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
Shreyaskumar Patel, Margaret von Mehren, Damon R Reed, et al.
Cancer Communications (London, England)
|
May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2013
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates
Janelle M Meyer, Kelly S Perlewitz, James B Hayden, et al.
Journal of Gynecologic Oncology
|
April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Young Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
JAMA Oncology
|
February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033
Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Page
of 12